Literature DB >> 14506838

Isoprenoid alcohols restore protein isoprenylation in a time-dependent manner independent of protein synthesis.

Susan E Ownby1, Raymond J Hohl.   

Abstract

Mevalonic acid derivatives are required for the isoprenylation of a variety of growth-regulating proteins. Treatment of NIH3T3 cells with lovastatin (LOV), an HMG-CoA reductase inhibitor, depletes cells of these derivatives and impairs isoprenylation of RAS and RAS-related proteins. In LOV-treated cells, farnesol (FOH) and geranylgeraniol (GGOH) restore RAS and Rap1 isoprenylation, respectively. In this study, we further characterize the manner in which these isoprenoid alcohols are utilized for protein isoprenylation. Over a 48-h time span, FOH is unable to maintain RAS isoprenylation in the continuing presence of LOV, whereas GGOH is able to maintain Rap1 isoprenylation in the presence of LOV at all times tested. When cells are pretreated with LOV, the ability of both FOH and GGOH to restore protein isoprenylation is time dependent; as the LOV pretreatment time increases, the time required for FOH and GGOH to restore isoprenylation also increases. Despite this time dependence, the ability of FOH and GGOH to restore protein isoprenylation is not dependent on new protein synthesis and does not require alcohol dehydrogenase. These data support the existence of and further characterize the isoprenoid shunt, a novel metabolic pathway that utilizes FOH and GGOH for protein isoprenylation. The enzymes of the isoprenoid shunt are constitutively expressed, their activity may be modulated by isoprenoid depletion, and they are differentially regulated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506838     DOI: 10.1007/s11745-003-1123-8

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  37 in total

1.  Metabolism of farnesol: phosphorylation of farnesol by rat liver microsomal and peroxisomal fractions.

Authors:  D Westfall; N Aboushadi; J E Shackelford; S K Krisans
Journal:  Biochem Biophys Res Commun       Date:  1997-01-23       Impact factor: 3.575

2.  Directed cell killing (apoptosis) in human lymphoblastoid cells incubated in the presence of farnesol: effect of phosphatidylcholine.

Authors:  J S Haug; C M Goldner; E M Yazlovitskaya; P A Voziyan; G Melnykovych
Journal:  Biochim Biophys Acta       Date:  1994-08-11

3.  Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, AND RhoB.

Authors:  Sarah A Holstein; Christine L Wohlford-Lenane; Raymond J Hohl
Journal:  J Biol Chem       Date:  2002-01-11       Impact factor: 5.157

4.  Geranylgeraniol promotes entry of UT-2 cells into the cell cycle in the absence of mevalonate.

Authors:  D C Crick; D A Andres; C J Waechter
Journal:  Exp Cell Res       Date:  1997-03-15       Impact factor: 3.905

5.  Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha.

Authors:  K Hanley; L G Kömüves; D C Ng; K Schoonjans; S S He; P Lau; D D Bikle; M L Williams; P M Elias; J Auwerx; K R Feingold
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

6.  Utilization of geranylgeraniol for protein isoprenylation in C6 glial cells.

Authors:  D C Crick; C J Waechter; D A Andres
Journal:  Biochem Biophys Res Commun       Date:  1994-11-30       Impact factor: 3.575

7.  Differential effects of monoterpenes and lovastatin on RAS processing.

Authors:  R J Hohl; K Lewis
Journal:  J Biol Chem       Date:  1995-07-21       Impact factor: 5.157

8.  Differences in sensitivity to farnesol toxicity between neoplastically- and non-neoplastically-derived cells in culture.

Authors:  I Adany; E M Yazlovitskaya; J S Haug; P A Voziyan; G Melnykovych
Journal:  Cancer Lett       Date:  1994-05-16       Impact factor: 8.679

9.  Identification of a nuclear receptor that is activated by farnesol metabolites.

Authors:  B M Forman; E Goode; J Chen; A E Oro; D J Bradley; T Perlmann; D J Noonan; L T Burka; T McMorris; W W Lamph; R M Evans; C Weinberger
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

10.  Human liver alcohol dehydrogenases catalyze the oxidation of the intermediary alcohols of the shunt pathway of mevalonate metabolism.

Authors:  W M Keung
Journal:  Biochem Biophys Res Commun       Date:  1991-01-31       Impact factor: 3.575

View more
  6 in total

1.  Roles of rat and human aldo-keto reductases in metabolism of farnesol and geranylgeraniol.

Authors:  Satoshi Endo; Toshiyuki Matsunaga; Chisato Ohta; Midori Soda; Ayano Kanamori; Yukio Kitade; Satoshi Ohno; Kazuo Tajima; Ossama El-Kabbani; Akira Hara
Journal:  Chem Biol Interact       Date:  2010-12-25       Impact factor: 5.192

2.  Metabolically regulated endoplasmic reticulum-associated degradation of 3-hydroxy-3-methylglutaryl-CoA reductase: evidence for requirement of a geranylgeranylated protein.

Authors:  Gil S Leichner; Rachel Avner; Dror Harats; Joseph Roitelman
Journal:  J Biol Chem       Date:  2011-07-21       Impact factor: 5.157

3.  In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors.

Authors:  Jacqueline E Reilly; Xiang Zhou; Huaxiang Tong; Craig H Kuder; David F Wiemer; Raymond J Hohl
Journal:  Biochem Pharmacol       Date:  2015-05-04       Impact factor: 5.858

4.  Geranylgeranyl pyrophosphate stimulates gamma-secretase to increase the generation of Abeta and APP-CTFgamma.

Authors:  Yan Zhou; Anitha Suram; Chitra Venugopal; Annamalai Prakasam; Suizhen Lin; Yuan Su; Baolin Li; Steven M Paul; Kumar Sambamurti
Journal:  FASEB J       Date:  2007-07-31       Impact factor: 5.191

5.  Rab GTPase prenylation hierarchy and its potential role in choroideremia disease.

Authors:  Monika Köhnke; Christine Delon; Marcus L Hastie; Uyen T T Nguyen; Yao-Wen Wu; Herbert Waldmann; Roger S Goody; Jeffrey J Gorman; Kirill Alexandrov
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

6.  Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.

Authors:  M Goffinet; M Thoulouzan; A Pradines; I Lajoie-Mazenc; Carolyn Weinbaum; J C Faye; S Séronie-Vivien
Journal:  BMC Cancer       Date:  2006-03-15       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.